TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05055128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Patients will receive Lansoprazole capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Patients will receive Lansoprazole capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Patients will receive Lansoprazole capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Patients will receive Lansoprazole capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Dummy
Description: Patients will receive matching placebo capsules for Lansoprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Dummy
Description: Patients will receive matching placebo capsules for Lansoprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Dummy
Description: Patients will receive matching placebo capsules for Lansoprazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Dummy
Description: Patients will receive matching placebo capsules for Lansoprazole.
Study: NCT05693155

Intervention type: BEHAVIORAL
Intervention: Voluntary self-exclusion from gambling ('Spelpaus')
Description: Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')

Intervention type: BEHAVIORAL
Intervention: Voluntary self-exclusion from gambling ('Spelpaus')
Description: Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
Study: NCT05395481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3849891
Description: Administered SC.
Study: NCT06266312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A multimodal prehabilitation programme
Description: 1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~   * 5 min. warm-up~  * 35 min. cycling at 40-60% of (HR reserve + resting HR)~  * 5-10 min. cool-down~2. + strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~* 3 min warm-up (20W)~* 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week.
Study: NCT05395481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3849891
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT06475170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: proximal gastrectomy combined with 'λ+α' double-tract anastomosis
Description: 1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal gastrectomy combined with 'λ+α' double-tract anastomosis
Description: 1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；
Study: NCT01048151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFerade™ Biologic
Description: AdGVEGR.TNF.11D
Study: NCT05426291

Intervention type: OTHER
Intervention: BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?
Description: In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.

Intervention type: OTHER
Intervention: BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?
Description: In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
Study: NCT04980222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
Study: NCT06022601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DNA Nudge
Description: DNA Nudge wearable, DNA-based dietary advice
Study: NCT05660863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-08 24 mg/day
Description: Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-08 60 mg/day
Description: Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
Study: NCT06148779

Intervention type: BEHAVIORAL
Intervention: Digitally delivered first-line treatment for osteoarthritis
Description: Digitally delivered first-line for osteoarthritis through the caregiver Joint Academy.

Intervention type: BEHAVIORAL
Intervention: Face-to-face first-line treatment for osteoarthritis
Description: First-line for osteoarthritis delivered at a primary care clinic face-to-face with reported data to the BOA registry.
Study: NCT05876351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
Study: NCT04411823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP measurement
Description: EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
Study: NCT06105801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial ultrasound with transbronchial needle aspiration
Description: Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound with transbronchial needle aspiration
Description: Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Participants will undergo Bronchoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Participants will undergo Bronchoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Participants will undergo Cryobiopsy
Study: NCT06427369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radioconjugate
Description: 1241-hJAA-F11 IV administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: PET/CT Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: PET/CT Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography and Computed Tomography Scan
Description: FDG PET/CT Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Blood sample collection imaging
Study: NCT06638398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo standard of care Computed Tomography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo standard of care Computed Tomography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Procedure
Description: Receive a Virtual Nodule Clinic radiomic prediction score obtained in Optellum software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care lung nodule management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care lung nodule management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary Studies
Study: NCT04822883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RL-007
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RL-007 Matching Placebo
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
Study: NCT06244823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab Prefilled Syringe
Description: MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
Study: NCT05215145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Navigator Bundle
Description: The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
Study: NCT06282393

Intervention type: DEVICE
Group type: OTHER
Intervention: FibriCheck recordings
Description: PPG and single-lead ECG measurements
Study: NCT06238271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acriva BB UDM 611
Description: Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
Study: NCT05103917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: CXCR4 inhibitor
Study: NCT04906876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as a 90-minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as a 90-minute IV infusion
Study: NCT05702203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Music Therapy
Description: Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
Study: NCT05160675

Intervention type: OTHER
Description: No intervention

Intervention type: OTHER
Description: No intervention
Study: NCT04496674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1 and Toczilizumab
Description: Adminsitration of CC-1 and Toczilizumab
Study: NCT05478902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Exercise protocol for rotator cuff related shoulder pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: High Energy Extracorporeal Shockwave Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Guided Percutaneous Irrigation
Description: Two sessions of Ultrasound-Guided Percutaneous Irrigation
Study: NCT06048341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Study: NCT04301674

Intervention type: DEVICE
Intervention: Breath Biopsy
Description: ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)

Intervention type: DEVICE
Intervention: Breath Biopsy
Description: ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
Study: NCT05717985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified combined approach
Description: A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: de-epithelized gingival graft
Description: Only dressing material will be placed at the donor site after graft harvesting
Study: NCT06226974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: * Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: * Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation.
Study: NCT06158854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383 (Etentamig)
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383 (Etentamig)
Description: Intravenous Infusion
Study: NCT05972239

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pulmonary rehabilitation program
Description: Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training added on standard pulmonary rehabilitation
Description: Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
Study: NCT06492031

Intervention type: DRUG
Intervention: Icodextrin Peritoneal Dialysis Solution
Description: The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.

Intervention type: DRUG
Intervention: Glucose Peritoneal Dialysis Solution
Description: The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
Study: NCT06219603

Intervention type: OTHER
Intervention: survey
Description: questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases

Intervention type: OTHER
Intervention: survey
Description: questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases

Intervention type: OTHER
Intervention: survey
Description: questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases

Intervention type: OTHER
Intervention: survey
Description: questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases

Intervention type: OTHER
Intervention: survey
Description: questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
Study: NCT06158854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383 (Etentamig)
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383 (Etentamig)
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383 (Etentamig)
Description: Intravenous Infusion
Study: NCT06473623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation
Description: Non-invasive Auricular Fiber Vagus Nerve Stimulation (afVNS)
Study: NCT05603143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir
Description: Tablets administered orally without regard to food.